Safety and Efficacy of Tideglusib in Congenital Myotonic Dystrophy
Status:
Enrolling by invitation
Trial end date:
2023-03-28
Target enrollment:
Participant gender:
Summary
This is an open-label extension phase 2/3 study for children and adolescents with Congenital
Myotonic Dystrophy (Congenital DM1) who participated in and completed the preceding
AMO-02-MD-2-003 study.